[1] |
Liu J, Zha Y, Zhang P, et al. The association between serum complement 4 and kidney disease progression in idiopathic membranous nephropathy: a multicenter retrospective cohort study[J]. Front Immunol, 2022, 13: 896654.
doi: 10.3389/fimmu.2022.896654
|
[2] |
Wang YN, Feng HY, Nie X, et al. Recent advances in clinical diagnosis and pharmacotherapy options of membranous nephropathy[J]. Front Pharmacol, 2022, 13: 907108.
doi: 10.3389/fphar.2022.907108
|
[3] |
中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J]. 中华儿科杂志, 2017, 55(10): 729-734.
|
[4] |
王忍. 儿童原发性膜性肾病研究进展[J]. 临床儿科杂志, 2021, 39(7): 549-552.
|
[5] |
Alsharhan L, Beck LJ. Membranous nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 77(3): 440-453.
doi: 10.1053/j.ajkd.2020.10.009
pmid: 33487481
|
[6] |
Oto OA, Demir E, Mirioglu S, et al. Clinical significance of glomerular C3 deposition in primary membranous nephropathy[J]. J Nephrol, 2021, 34(2): 581-587.
doi: 10.1007/s40620-020-00915-w
pmid: 33387338
|
[7] |
王楠楠. 儿童特发性膜性肾病诊疗进展[J]. 临床儿科杂志, 2021, 39(6): 476-480.
|
[8] |
Fervenza FC, Glassock RJ. Molecular characterization of membranous nephropathy: quo vadis?[J]. J Am Soc Nephrol, 2022, 33(6): 1057-1059.
doi: 10.1681/ASN.2022040395
pmid: 35577559
|
[9] |
Teisseyre M, Cremoni M, Boyer-Suavet S, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy[J]. Front Immunol, 2022, 13: 859419.
doi: 10.3389/fimmu.2022.859419
|
[10] |
Horvatic I, Ljubanovic DG, Bulimbasic S, et al. Prognostic significance of glomerular and tubulointerstitial morphometry in idiopathic membranous nephropathy[J]. Pathol Res Pract, 2012, 208(11): 662-667.
doi: 10.1016/j.prp.2012.08.004
pmid: 22995635
|
[11] |
Chinello C, de Haan N, Capitoli G, et al. Definition of IgG subclass-specific glycopatterns in idiopathic membranous nephropathy: aberrant IgG glycoforms in blood[J]. Int J Mol Sci, 2022, 23(9): 4664.
doi: 10.3390/ijms23094664
|
[12] |
Tsuboi N, Kawamura T, Miyazaki Y, et al. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy[J]. Nephrol Dial Transplant, 2011, 26: 3555-3560.
doi: 10.1093/ndt/gfr399
|
[13] |
Ponticelli C, Patrizia P, Del Vecchio L, et al. The evolution of the therapeutic approach to membranous nephropathy[J]. Nephrol Dial Transplant, 2021, 36: 768-773.
doi: 10.1093/ndt/gfaa014
|
[14] |
Yoshimoto K, Yokoyama H, Wada T, et al. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy[J]. Kidney Int, 2004, 65(1): 148-153.
pmid: 14675045
|
[15] |
Cattran D. Management of membranous nephropathy: when and what for treatment[J]. J Am Soc Nephrol, 2005, 16(5): 1188-1194.
pmid: 15800117
|
[16] |
Sprangers B, Bomback AS, Cohen SD, et al. Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center[J]. Am J Nephrol, 2012, 36(1): 78-89.
doi: 10.1159/000339628
pmid: 22739228
|
[17] |
Spranger J, Homberg A, Sonnberger M, et al. Reporting guidelines for Delphi techniques in health sciences: a methodological review[J]. Z Evid Fortbild Qual Gesundhwes, 2022, 172: 1-11.
doi: 10.1016/j.zefq.2022.04.025
pmid: 35718726
|